← RHYTHM PHARMACEUTICALS, INC. (RYTM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Pharmaceutical Preparations · market cap $6.7B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 2
Pipeline
7
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Rhythm Pharmaceuticals (RYTM) is a rare-disease pharmaceutical company with 283 employees and a ~$7.4B market cap, built around setmelanotide, an MC4R pathway agonist targeting genetic and hypothalamic obesities. The company has two high-importance Phase 3 readouts for setmelanotide expected in the next ~9 months, against a backdrop of razor-thin cash runway (~4 months, $62M cash vs. $46M net debt) that almost certainly necessitates near-term capital raising.
The catalyst path
- 2026-10-31 (est.)Phase 2 · Setmelanotideimp 7/10
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-03-13 (est.)Phase 3 · Setmelanotideimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Setmelanotide 2 mg | Phase 3 | Bardet-Biedl Syndrome |
| LB54640 | Phase 2 | Hypothalamic Obesity |
| Setmelanotide | Phase 3 | Genetic Obesity |
| Part C: RM-718 | Phase 2 | Hypothalamic Obesity |
| Class I or III Antiarrhythmic Medications | Phase 3 | Atrial Fibrillation |
| Diuretics | Phase 2 | Heart Failure |
| Flecainide or Sotalol or Propafenone | Phase 3 | Paroxysmal Atrial Fibrillation |
Price & technical context
3-month
-18.2%
6-month
+6.0%
12-month
-7.5%
52-wk range
$75.82–$117.62
vs 50-day MA
-11.6%
vs 200-day MA
-5.6%
Realized vol
46.3%
Max drawdown
-35.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RYTM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.